Source-grounded facts extracted from Annovis Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Annovis Bio, Inc. shareholders approved Advisory (Non-Binding) Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-17 meeting.
“The compensation of the Company's named executive officers was approved b y the stockholders o n an advisory (non-binding basis), by the following vote: Broker Non-Vote For Against Abstain Broker Non-Vote 8,067,931 901,342 185,701 12,550,139”
Annovis Bio, Inc. shareholders approved Amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares at the 2026-06-17 meeting.
“The amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to i ncrease the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote: For Against Abstain Broker Non-Vote 8,089,891 899,671 165,409 12,550,142”
Annovis Bio, Inc. shareholders approved Ratification of the Company's Independent Auditors at the 2026-06-17 meeting.
“The ratification of the appointment of Ernst & Young LLP was approved by stockholders by the following vote: For Against Abstain 20,634,176 568,155 502,782”
Annovis Bio, Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.
“Election of Directors All of the following five nominees were elected to the Company's Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.”
Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at approximately $15 million (effective 2026-05-20).
“On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase up to an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).”
Annovis Bio, Inc. reported first quarter ended March 31, 2026 results: EPS $0.63 basic and diluted net loss per common share.
“Annovis reported a $0.63 basic and diluted net loss per common share for the three months ended March 31, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended March 31, 2025.”
Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at Combined offering price of $1.90 per Share and accompanying Warrant, gross proceeds ~$10 million (effective 2026-04-09).
“On April 9, 2026, Annovis Bio, Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase an aggregate of 5,263,156 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).”
Annovis Bio, Inc. reported financial results for the year ended December 31, 2025.
“On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025.”
Andrew Walsh was appointed as Principal Financial Officer at Annovis Bio, Inc..
“On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.”
Annovis Bio, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).
“March 26, 2025, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. As set forth in the Notice, as of March 25, 2025, the 30 trading-day average global market capitalization of the Company was”
Maria Maccecchini was appointed as Principal Financial Officer on an interim basis at Annovis Bio, Inc..
“Maria Maccecchini will continue to serve as principal financial officer on an interim basis.”
William Fricker departed as Interim Chief Financial Officer at Annovis Bio, Inc..
“On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.”
Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.”
Maria Maccecchini was appointed as interim principal financial officer at Annovis Bio, Inc..
“On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.”
Henry Hagopian departed as Chief Financial Officer at Annovis Bio, Inc..
“Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.”
Annovis Bio, Inc. entered into Common Stock Purchase Agreement with the Equity Line investor (the "ELOC Purchaser") valued at up to 2,051,428 shares (effective 2024-04-25).
“On April 25, 2024, Annovis Bio, Inc., a Delaware corporation (the “Company”), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with the Equity Line investor (the “ELOC Purchaser”), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to 2,051,428 shares of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) (but subject to the limitations described below).”
Annovis Bio, Inc. reported fourth quarter and full year 2023 results: net income $22.2 million.
“today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.”
Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2024-03-21).
“On March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).”
Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds of $1,025,000 (effective 2024-03-15).
“On March 15, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).”
Annovis Bio, Inc. entered into Underwriting Agreement with Cannacord Genuity LLC (effective 2023-10-31).
“On October 31, 2023, Annovis Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cannacord Genuity LLC, as representative of the several underwriters (the “Representative”) in connection with the issuance and sale by the Company in a public offering of an aggregate of (i) 1,250,000 shares of the Company’s common stock (the “Shares”) and (ii) warrants to purchase 1,250,000 shares of the Company’s common stock (the “Warrants”), at a public offering price of $6.00 per unit (the “Offering”), less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-252625) and a related prospectus supplement filed with the Securities and Exchange Commission (the “SEC”).”
Annovis Bio, Inc.: Amended certificate of incorporation to increase authorized common shares from 35,000,000 to 70,000,000 (effective 2023-06-15).
“At the Annual Meeting, among other things, the stockholders of the Company approved an amendment to the Annovis Bio, Inc. Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 35,000,000 to 70,000,000 shares (the “Charter Amendment’).”
Annovis Bio, Inc. shareholders approved Amendment of the 2020 Equity Incentive Plan to increase authorized shares from 35,000,000 to 70,000,000 at the 2023-06-16 meeting.
“The amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 35,000,000 to 70,000,000 was approved, with the following votes tabulated: For Against Abstain 5,699,648 633,577 9,357”
Annovis Bio, Inc. shareholders approved Election of Directors at the 2023-06-16 meeting.
“The following director nominees were elected to serve as directors of the Company, with the following votes tabulated: For Withheld Broker Non-Vote Michael Hoffman 3,994,452 40,827 2,307,303 Maria Maccecchini 3,998,045 37,234 2,307,303 Claudine Bruck 3,941,691 93,588 2,307,303 Reid McCarthy 3,993,879 41,400 2,307,303 Mark White 3,987,711 47,568 2,307,303”
Annovis Bio, Inc. engaged Ernst & Young LLP as its auditor.
“Engagement of New Independent Registered Public Accounting Firm Effective May 25, 2023, the Audit Committee approved the appointment of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Annovis Bio, Inc. dismissed WithumSmith+Brown PC as its auditor.
“Dismissal of Independent Registered Public Accounting Firm On May 25, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Annovis Bio, Inc. (the “Company”) dismissed WithumSmith+Brown PC (“Withum”) as the Company’s independent registered public accounting firm.”
Annovis Bio, Inc. terminated ATM Equity Offering Sales Agreement with BofA Securities, Inc. and ThinkEquity LLC valued at up to $50,000,000 (effective 2023-04-09).
“On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023, pursuant to Section 9(a) of the Sales Agreement.”
Annovis Bio, Inc. entered into Sales Agreement with BofA Securities, Inc. and ThinkEquity LLC valued at up to $50.0 million (effective 2023-03-31).
“On March 31, 2023, Annovis Bio, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement SM (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million (the “Shares”).”
Annovis Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021.
“On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update.”
Annovis Bio, Inc. reported that prior financial statements should not be relied upon.
“ear ended December 31, 2022 the restated financial statements for each of the Non-Reliance Periods (“Restatements”). As a result, the unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on. S imilarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing”
Jeffrey B. McGroarty departed as Chief Financial Officer at Annovis Bio, Inc..
“Jeffrey B. McGroarty, formerly Chief Financial Officer, Treasurer and Corporate Secretary of the Company, was stepping down from his role to pursue other opportunities.”
Jeffrey McGroarty departed as Chief Financial Officer at Annovis Bio, Inc..
“Mr. McGroarty will leave the Company to pursue other interests.”
Henry Hagopian III was appointed as Chief Financial Officer at Annovis Bio, Inc..
“On August 29, 2022, the Board of Directors of Annovis Bio, Inc. (the “Company”) appointed Henry Hagopian III, age 54, as Chief Financial Officer of the Company, effective immediately, to replace Jeffrey McGroarty.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.